Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer

Laboratory Investigation

Volumn 94, Issue 9, 2014, Pages 950-965

  Viennois, Emilie ^a,b   Xiao, Bo ^a   Ayyadurai, Saravanan ^a   Wang, Lixin ^a,b   Wang, Peng G ^a,c   Zhang, Quan ^c   Chen, Yue ^c   Merlin, Didier ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; COLITIS; COLORECTAL NEOPLASMS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SESQUITERPENES, GUAIANE;

EID: 84906829810     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.89     Document Type: Article

References (53)

1. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease:Incidence, prevalence, and environmental influences. Gastroenterology2004;126:1504-1517.
2. Saleh M, Elson CO. Experimental inflammatory bowel disease: Insightsinto the host-microbiota dialog. Immunity 2011;34:293-302.
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis ofinflammatory bowel disease. Nature 2011;474:307-317.
4. Sakata K, Yamashita T, Maeda M, et al. Cloning of a lymphatic peptide/histidine transporter. Biochem J 2001;356(Pt 1):53-60.
5. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer.Gastroenterology 2010;138:2101-2114 e2105.
6. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer JClin 2011;61:69-90.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
8. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: Linkingmicrobial infections to chronic inflammation and cancer. Cell2006;124:823-835.
9. Viennois E, Chen F, Merlin D. NF-kappaB pathway in colitis- associatedcancers. Transl Gastrointest Cancer 2013;2:21-29.
10. Heinrich M, Robles M, West JE, et al. Ethnopharmacology of Mexicanasteraceae (Compositae). Annu Rev Pharmacol Toxicol 1998;38:539-565.
11. Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene lactonesspecifically inhibit activation of NF-kappa B by preventing thedegradation of I kappa B-alpha and I kappa B-beta. J Biol Chem1998;273:1288-1297.
12. Saadane A, Masters S, DiDonato J, et al. Parthenolide inhibits IkappaBkinase, NF-kappaB activation, and inflammatory response in cysticfibrosis cells and mice. Am J Respir Cell Mol Biol 2007;36:728-736.
13. Zhao ZJ, Xiang JY, Liu L, et al. Parthenolide, an inhibitor of the nuclearfactor-kappaB pathway, ameliorates dextran sulfate sodium-inducedcolitis in mice. Int Immunopharmacol 2012;12:169-174.
14. Kim JH, Liu L, Lee SO, et al. Susceptibility of cholangiocarcinoma cellsto parthenolide-induced apoptosis. Cancer Res 2005;65:6312-6320.
15. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolidereverses resistance of breast cancer cells to tumor necrosis factorrelatedapoptosis-inducing ligand through sustained activation ofc-Jun N-terminal kinase. Oncogene 2004;23:7330-7344.
16. Park JH, Liu L, Kim IH, et al. Identification of the genes involved inenhanced fenretinide-induced apoptosis by parthenolide in humanhepatoma cells. Cancer Res 2005;65:2804-2814.
17. Yip-Schneider MT, Wu H, Njoku V, et al. Effect of celecoxib and thenovel anti-cancer agent, dimethylamino-parthenolide, in a developmentalmodel of pancreatic cancer. Pancreas 2008;37:e45-e53.
18. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols andcalcium in parthenolide-induced apoptosis in human colorectal cancercells. Cancer Lett 2004;208:143-153.
19. Neelakantan S, Nasim S, Guzman ML, et al. Aminoparthenolides asnovel anti-leukemic agents: Discovery of the NF-kappaB inhibitor,DMAPT (LC-1). Bioorg Med Chem Lett 2009;19:4346-4349.
20. Zhang Q, Lu Y, Ding Y, et al. Guaianolide sesquiterpene lactones, asource to discover agents that selectively inhibit acute myelogenousleukemia stem and progenitor cells. J Med Chem 2012;55:8757-8769.
21. Shanmugam R, Kusumanchi P, Cheng L, et al. A water-solubleparthenolide analogue suppresses in vivo prostate cancer growth bytargeting NFkappaB and generating reactive oxygen species. Prostate2010;70:1074-1086.
22. Shanmugam R, Kusumanchi P, Appaiah H, et al. A water solubleparthenolide analog suppresses in vivo tumor growth of two tobaccoassociatedcancers, lung and bladder cancer, by targeting NF-kappaBand generating reactive oxygen species. Int J Cancer 2011;128:2481-2494.
23. Jin P, Madieh S, Augsburger LL. The solution and solid state stabilityand excipient compatibility of parthenolide in feverfew. AAPS Pharm Sci Tech 2007;8:E105.
24. Zhai JD, Li D, Long J, et al. Biomimetic semisynthesis of arglabin fromparthenolide. J Org Chem 2012;77:7103-7107.
25. Ding YH, Fan HX, Long J, et al. The application of Heck reaction in thesynthesis of guaianolide sesquiterpene lactones derivatives selectivelyinhibiting resistant acute leukemic cells. Bioorg Med Chem Lett2013;23:6087-6092.
26. Ma WW, Shi QQ, Ding YH, et al. Synthesis of micheliolide derivativesand their activities against AML progenitor cells. Molecules 2013;18:5980-5992.
27. Viennois E, Chen F, Laroui H, et al. Dextran sodium sulfate inhibits theactivities of both polymerase and reverse transcriptase: Lithiumchloride purification, a rapid and efficient technique to purify RNA.BMC Res Notes 2013;6:360.
28. Charrier L, Yan Y, Driss A, et al. ADAM-15 inhibits wound healing inhuman intestinal epithelial cell monolayers. Am J Physiol GastrointestLiver Physiol 2005;288:G346-G353.
29. Laroui H, Sitaraman SV, Merlin D. Gastrointestinal delivery of antiinflammatorynanoparticles. Methods Enzymol 2012;509:101-125.
30. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation andtumorigenesis in a mouse model of colitis-associated cancer. Cell2004;118:285-296.
31. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-inducedtype I IFN protects mice from experimental colitis. J Clin Invest2005;115:695-702.
32. Chassaing B, Srinivasan G, Delgado MA, et al. Fecal lipocalin 2, asensitive and broadly dynamic non-invasive biomarker for intestinalinflammation. PLoS One 2012;7:e44328.
33. Burd DA, Greco RM, Regauer S, et al. Hyaluronan and wound healing: Anew perspective. Br J Plast Surg 1991;44:579-584.
34. Clayton HA, London NJ, Colloby PS, et al. The effect of capsulecomposition on the biocompatibility of alginate-poly-l-lysine capsules.J Microencapsul 1991;8:221-233.
35. Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticlestargeted to the colon with polysaccharide hydrogel reduce colitis in amouse model. Gastroenterology 2010;138:843-853, e841-842.
36. Azab AK, Orkin B, Doviner V, et al. Crosslinked chitosan implants aspotential degradable devices for brachytherapy: In vitro and in vivoanalysis. J Control Release 2006;111:281-289.
37. Tozaki H, Odoriba T, Okada N, et al. Chitosan capsules for colonspecificdrug delivery: Enhanced localization of 5-aminosalicylic acid inthe large intestine accelerates healing of TNBS-induced colitis in rats.J Control Release 2002;82:51-61.
38. Mladenovska K, Raicki RS, Janevik EI, et al. Colon-specific delivery of5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm 2007;342:124-136.
39. Shi C, Zhu Y, Ran X, et al. Therapeutic potential of chitosanand its derivatives in regenerative medicine. J Surg Res 2006;133:185-192.
40. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis ofinflammatory bowel disease. Annu Rev Med 2000;51:289-298.
41. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha inserum of patients with inflammatory bowel disease as measured by ahighly sensitive immuno-PCR. Clin Chem 2001;47:1297-1301.
42. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory boweldisease. Dig Dis Sci 1992;37:818-826.
43. Wang J, Fu YX. Tumor necrosis factor family members and inflammatorybowel disease. Immunol Rev 2005;204:144-155.
44. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure ofinfliximab for Crohn's disease. Lancet 2000;356:1475-1479.
45. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatmentin inflammatory bowel disease. Gastroenterology 2004;126:1593-1610.
46. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's Diseasepatients treated with infliximab: A long-term multicenter matched pairstudy. Inflamm Bowel Dis 2011;17:758-766.
47. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibodyin children and young adults with inflammatory bowel diseasereceiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502-508.
48. Parashette KR, Makam RC, Cuffari C. Infliximab therapy in pediatricCrohn's disease: A review. Clin Exp Gastroenterol 2010;3:57-63.
49. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and otherimmunomodulating drugs in patients with inflammatory boweldisease and the risk of serious bacterial infections. AlimentPharmacol Ther 2009;30:253-264.
50. Sherlock ME, Bandsma R, Ota K, et al. Severe neutropenia followinginfliximab treatment in a child with ulcerative colitis. Inflamm Bowel Dis 2011;17:E17-E18.
51. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions toinfliximab: Aetiology, immunogenicity and risk factors in patients withinflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-58.
52. Veereman-Wauters G, de Ridder L, Veres G, et al. Risk of infection andprevention in pediatric patients with IBD: ESPGHAN IBD Porto Groupcommentary. J Pediatr Gastroenterol Nutr 2012;54:830-837.
53. Iborra M, Beltran B, Bastida G, et al. Infliximab and adalimumabinducedpsoriasis in Crohn's disease: A paradoxical side effect. J CrohnsColitis 2011;5:157-161.